Related Experiment Video

Updated: Jul 30, 2025

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.1K

Metalloproteinases and Hypertrophic Cardiomyopathy: A Systematic Review

Giuseppe Filiberto Serraino1, Federica Jiritano1, Davide Costa2

  • 1Department of Experimental and Clinical Medicine, "Magna Graecia" University of Catanzaro, 88100 Catanzaro, Italy.

Biomolecules
|May 16, 2023
PubMed

Insights

Matrix metalloproteinases (MMPs) are elevated in hypertrophic cardiomyopathy (HCM) patients. Monitoring MMPs and their inhibitors (TIMPs) may offer a non-invasive method for evaluating HCM progression and treatment effectiveness.

Area of Science:

  • Cardiovascular Research
  • Biochemistry
  • Genetics

Background:

  • Hypertrophic cardiomyopathy (HCM) is a genetic disorder characterized by abnormal extracellular matrix collagen turnover.
  • Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) show altered release patterns in HCM patients.

Approach:

  • A systematic review was conducted to consolidate current knowledge on MMP profiles in HCM.
  • Literature screening spanned from July 1975 to November 2022, selecting 16 trials with 892 participants meeting inclusion criteria.

Key Points:

  • MMP levels, particularly MMP2, were significantly higher in HCM patients compared to healthy controls.
  • MMPs have been utilized as biomarkers to assess outcomes following surgical and percutaneous interventions in HCM.
  • Altered collagen turnover in the cardiac extracellular matrix is a hallmark of HCM.

Conclusions:

  • Understanding the molecular regulation of cardiac extracellular matrix collagen turnover is crucial for HCM management.
  • Monitoring MMPs and TIMPs presents a potential avenue for non-invasive evaluation and assessment of hypertrophic cardiomyopathy.

Keywords:
biomarkerscollagenextracellular matrixhypertrophic cardiomyopathymatrix metalloproteinases

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.2K
An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

5.8K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
17
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
19
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
25
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
12
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
18
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
12